Теракурмин: биодоступная куркумин с клинически подтвержденным эффектом для когнитивного здоровья и борьбы с воспалением старения

As populations age across North America, Europe, and Asia, healthy aging – often reframed as “healthspan” rather than lifespan – has become a central priority for consumers and the nutraceutical industry alike. Increasingly, the focus is not only on longevity, but on maintaining quality of life, functional independence and physiological resilience as people age. Industry analyses identify healthy aging as one of the fastest-growing global categories. This shift is driving demand for clinically substantiated ingredients capable of addressing multiple, interconnected aspects of aging biology. Within this evolving landscape, chronic low-grade inflammation – commonly referred to as “inflammaging” – has emerged as a unifying biological concept. Rather than representing a disease state, inflammaging is widely discussed in scientific literature as an age-associated process that may influence cognitive performance, joint and mobility function, cardiovascular health, and immune-related balance. As a result, ingredients supported by human clinical research across multiple domains are increasingly valued in integrated healthy aging strategies. A clinically evaluated foundation for cognitive function and brain health research Age-related changes in cognitive function have been associated in scientific literature with inflammatory pathways, oxidative stress, and altered neuronal signaling. Against this background, Theracurmin® – a high-bioavailability curcumin formulation – has been evaluated in long-term human clinical research focused on cognitive assessment parameters.1 One notable study includes an 18‑month randomized, double-blind, placebo-controlled trial in non-demented older adults, among the longest clinical evaluations conducted with curcumin.1 Over the study period, assessments related to memory and attention were evaluated, positioning Theracurmin within research frameworks exploring cognitive function in healthy aging populations. A key enabling factor for this research is bioavailability. Conventional curcumin is widely recognized for its poor absorption, limiting its suitability for long-term human studies. By overcoming these bioavailability constraints, Theracurmin allows for consistent systemic exposure, supporting extended clinical evaluation in aging-related research settings. Joint and mobility support as a tangible marker of healthy aging Joint comfort, mobility and physical function remain among the most visible and consumer-relevant indicators of healthy aging. Inflammatory mechanisms are frequently assessed alongside pain, walking ability and functional mobility outcomes in joint-related clinical studies, reflecting the close link between inflammation and musculoskeletal health. Theracurmin has been evaluated in multiple randomized, double-blind, placebo-controlled clinical trials involving individuals with knee osteoarthritis.2 These studies examined pain-related parameters, walking performance, and functional mobility scores. In addition, longer-term randomized trials – extending up to one year – have evaluated cartilage-related clinical markers. Together, these findings support the positioning of Theracurmin as an ingredient with documented clinical relevance in joint and mobility research, contributing to quality-of-life outcomes that are central to healthy aging formulations. Immune-related inflammation as a connecting mechanism Rather than treating immune health as a standalone endpoint, contemporary healthy aging research increasingly evaluates immune-related changes through the lens of inflammatory balance. Inflammaging is frequently discussed as a shared biological mechanism influencing multiple physiological systems over time. Human clinical studies involving Theracurmin have included the evaluation of inflammation-associated biomarkers, such as cytokine-related parameters including TNF‑α, within broader research designs. Importantly, these studies do not position the ingredient as an immune stimulant. Instead, they examine how inflammatory markers behave within healthy or aging populations.3 This perspective reinforces immune-related inflammation as a linking mechanism that connects cognitive function, joint health and other aging-related physiological outcomes under a unified healthy aging framework. Expanding the evidence base: Multi-domain clinical relevance Beyond brain and joint health, Theracurmin is supported by a broad clinical portfolio, with more than 34 human studies published in reputable scientific journals. These include publications associated with organizations such as the American Psychiatric Association and the American College of Cardiology, underscoring relevance not only for cognitive and mobility research, but also for cardiovascular-related scientific discourse. Additional areas of investigation include muscle recovery and physical performance, offering a supporting angle for sports nutrition and active aging applications. This multi-domain research footprint differentiates Theracurmin from standard curcumin ingredients that are often supported by limited or short-term data. High bioavailability, formulation flexibility and global safety Theracurmin is developed using proprietary Japanese technology designed to significantly enhance curcumin absorption, with human pharmacokinetic studies reporting 42 to 85 times higher bioavailability compared to standard curcumin. Improved absorption not only supports clinical research but also enables dose efficiency and formulation flexibility.4 From a product development perspective, Theracurmin is suitable for a wide range of delivery formats, including capsules, tablets, gummies and ready-to-drink (RTD) applications, making it highly relevant for R&D teams targeting diverse consumer preferences. In parallel, safety has been demonstrated across multiple studies involving diverse populations, including participants from North America, Asia and the Middle East, supporting global commercialization strategies. Japanese expertise as a mark of scientific precision The development of Theracurmin reflects a broader narrative of Japanese scientific expertise, emphasizing precision, quality, and innovation. In the healthy aging category – where credibility and consistency are critical – this “science of expertise” approach reinforces confidence among formulators, researchers, and brand owners alike. Looking ahead: Integrated, evidence-based healthy aging solutions As the healthy aging category continues to evolve, integrated, evidence-based approaches that address multiple physiological systems are expected to play an increasingly important role. Clinical research frameworks that examine cognitive function, physical mobility, cardiovascular relevance, and immune-related inflammation within a single context reflect a shift toward more holistic – yet scientifically grounded – product development. With its high bioavailability, extensive human clinical research across multiple health domains and globally relevant safety profile, Theracurmin aligns closely with this direction. The ingredient supports the development of healthspan-focused formulations, where quality of life, functional performance and inflammatory balance are addressed through a single, research-driven strategy. References - Small, G. W.; et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. The American Journal of Geriatric Psychiatry. 2018; 26:3. - Nakagawa, Y.; et al. The Efficacy and Safety of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A 6-Month Open-Labeled Prospective Study. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13. - Tanabe, Y.; et al. Attenuation of Indirect Markers of Eccentric Exercise-Induced Muscle Damage by Curcumin. Eur J Appl Physiol. 2015;115(9):1949-1957. - Morimoto T.; et al. Drinkable Preparation of Theracurmin Exhibits High Absorption Efficiency: A Single-Dose, Double-Blind, 4-Way Crossover Study. Biol Pharm Bull. 2013;36(11):1708-1714.